Early Detection and Diagnosis

You have full text access to this OnlineOpen article

The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients

  1. Shohei Honda1,2,
  2. Masayuki Haruta1,
  3. Waka Sugawara1,
  4. Fumiaki Sasaki3,
  5. Miki Ohira3,
  6. Tadashi Matsunaga3,
  7. Hiroaki Yamaoka3,
  8. Hiroshi Horie3,
  9. Naomi Ohnuma3,
  10. Akira Nakagawara3,
  11. Eiso Hiyama3,
  12. Satoru Todo2,
  13. Yasuhiko Kaneko1,3,†,*

Article first published online: 6 JUN 2008

DOI: 10.1002/ijc.23613

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 1117–1125, 1 September 2008

Additional Information

How to Cite

Honda, S., Haruta, M., Sugawara, W., Sasaki, F., Ohira, M., Matsunaga, T., Yamaoka, H., Horie, H., Ohnuma, N., Nakagawara, A., Hiyama, E., Todo, S. and Kaneko, Y. (2008), The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int. J. Cancer, 123: 1117–1125. doi: 10.1002/ijc.23613

Author Information

  1. 1

    Department of Cancer Diagnosis, Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan

  2. 2

    Department of General Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan

  3. 3

    Japanese Study Group for Pediatric Liver Tumor (JPLT), Hiroshima, Japan

  1. †

    Fax: +81-48-722-1739.

*Research Institute for Clinical Oncology, Saitama Cancer Center, 818 Komuro, Ina, Saitama, 362-0806, Japan

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 6 JUN 2008
  3. Manuscript Accepted: 6 MAR 2008
  4. Manuscript Received: 27 NOV 2007

Funded by

  • Ministry of Health, Labor and Welfare, Japan (for Third-term Comprehensive Control Research for Cancer)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (288K)

References

  • 1
    Perilongo G,Shafford EA. Liver tumours. Eur J Cancer 1999; 35: 953–8.
  • 2
    Perilongo G,Shafford S,Plaschkes J. SIOPEL trials using preoperative chemotherapy in hepatoblstoma. Lancet Oncol 2000; 1: 94–100.
  • 3
    Fuchs J,Rydzynski J,Von Schweinitz D,Bode U,Hecker H,Weinel P,Burger D,Harms D,Erttmann R,Oldhafer K,Mildenberger H. Pretreatment prognostic factors and treatment results in children with hepatoblastoma. Cancer 2002; 95: 172–82.
    Direct Link:
  • 4
    Haas JE,Muczynski KA,Krailo M,Ablin A,Land V,Vietti TJ,Hammond GD. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer 1989; 64: 1082–95.
    Direct Link:
  • 5
    Weber RG,Pietsch T,Von Schweinitz D,Lichter P. Characterization of genomic alterations in hepatoblastomas: a role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 2000; 157: 571–8.
  • 6
    Kumon K,Kobayashi H,Namiki T,Tsunematsu Y,Miyauchi J,Kikuta A,Horikoshi Y,Komada Y,Hatae Y,Eguchi H,Kaneko Y. Frequent increase of DNA copy number in the 2q24 chromosomal region and its association with a poor clinical outcome in hepatoblastoma: cytogenetic and comparative genomic hybridization analysis. Jpn J Cancer Res 2001; 92: 854–62.
  • 7
    Hiyama E,Yamaoka H,Matsunaga T,Hayashi Y,Ando H,Suita S,Horie H,Kaneko M,Sasaki F,Hashizume K,Nakagawara A,Ohnuma N, et al. High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma. Br J Cancer 2004; 91: 972–9.
  • 8
    Yamada S,Ohira M,Horie H,Ando K,Takayasu H,Suzuki Y,Sugano S,Hirata T,Goto T,Matsunaga T,Hiyama E,Hayashi Y, etal. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004; 23: 5901–11.
  • 9
    Sugawara W,Haruta M,Sasaki F,Watanabe N,Tsunematsu Y,Kikuta A,Kaneko Y. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr Blood Cancer 2007; 49: 240–9.
    Direct Link:
  • 10
    Koch A,Denkhaus D,Albrecht S,Leuschner I,Von Schweinitz D,Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res 1999; 59: 269–73.
  • 11
    Ohnishi H,Kawamura M,Hanada R,Kaneko Y,Tsunoda Y,Hongo T,Bessho F,Yokomori K,Hayashi Y. Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas. Genes Chromosomes Cancer 1996; 15: 187–90.
    Direct Link:
  • 12
    Taniguchi K,Roberts LR,Aderca IN,Dong X,Qian C,Murphy LM,Nagorney DM,Burgart LJ,Roche PC,Smith DI,Ross JA,Liu W. Mutational spectrum of β-catenin. AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002; 21: 4863–71.
  • 13
    Zhang Z,Sun D,Van DN,Tang A,Hu L,Huang G. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer 2006; 120: 32–8.
    Direct Link:
  • 14
    Hesson L,Dallol A,Minna JD,Maher ER,Latif F. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 2003; 22: 947–54.
  • 15
    Yoshikawa H,Matsubara K,Qian GS,Jackson P,Groopman JD,Manning JE,Harris CC,Herman JG. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29–35.
  • 16
    Dhillon VS,Shahid M,Husain SA. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer 2004; 3: 33.
  • 17
    Du Y,Carling T,Fang W,Piao Z,Sheu JC,Huang S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res 2001; 61: 8094–9.
  • 18
    Liu XQ,Chen HK,Zhang XS,Pan ZG,Li A,Feng QS,Long QX,Wang XZ,Zeng YX. Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. Int J Cancer 2003; 106: 60–5.
    Direct Link:
  • 19
    Lind GE,Skotheim RI,Fraga MF,Abeler VM,Esteller M,Lothe RA. Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1). J Pathol 2006; 210: 441–9.
    Direct Link:
  • 20
    Teitz T,Wei T,Valentine MB,Vanin EF,Grenet J,Valentine VA,Behm FG,Look AT,Lahti JM,Kidd VJ. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529–35.
  • 21
    Banelli B,Gelvi I,Di Vinci A,Scaruffi P,Casciano I,Allemanni G,Bonassi S,Tonini GP,Romani M. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 2005; 24: 5619–28.
  • 22
    Furuta J,Nobeyama Y,Umebayashi Y,Otsuka F,Kikuchi K,Ushijima T. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 2006; 66: 6080–6.
  • 23
    Matsunaga T,Sasaki F,Ohira M,Hashizume K,Hayashi A,Hayashi Y,Matsuyama T,Mugishima H,Ohnuma N. The role of surgery in the multimodal treatment for hepatoblastomas. Shounigan 2004; 41: 205–10 (in Japanese).
  • 24
    Hata Y. The clinical features and prognosis of hepatoblastoma: follow-up studies done on pediatric tumors enrolled in the Japanese Pediatric Tumor Registry between 1971 and 1980. Jpn J Surg 1990; 20: 498–502.
  • 25
    Sasaki F,Matsunaga T,Iwafuchi M,Hayashi Y,Ohkawa H,Ohira M,Okamatsu T,Sugito T,Tsuchida Y,Toyosaka A,Nagahara N,Nishihira H, et al. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) protocol-1: a report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 2002; 37: 851–6.
  • 26
    Brown J,Perilongo G,Shafford E,Keeling J,Pritchard J,Brock P,Dicks-Mireaux C,Phillips A,Vos A,Plaschkes J. Pretreatment prognostic factors for children with hepatoblastoma-results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL1. Eur J Cancer 2000; 36: 1418–25.
  • 27
    Herman JG,Graff JR,Myöhänen S,Nelkin BD,Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. PNAS 1996; 93: 9821–6.
  • 28
    Hoque MO,Begum S,Topaloglu O,Chatterjee A,Rosenbaum E,Van Criekinge W,Westra WH,Schoenberg M,Zahurak M,Goodman SN,Sidransky D. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006; 98: 996–1004.
  • 29
    Schmiemann V,Böcking A,Kazimirek M,Onogre AS,Gabbert HE,Kappes R,Gerharz CD,Grote HJ. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study. Clin Cancer Res 2005; 11: 7728–34.
  • 30
    Spugnardi M,Tommasi S,Dammann R,Pfeifer GP,Hoon DS. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003; 63: 1639–43.
  • 31
    Dammann R,Li C,Yoon JH,Chin PL,Bates S,Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25: 315–19.
  • 32
    Satoh Y,Nakagawachi T,Nakadate H,Kaneko Y,Masaki Z,Mukai T,Soejima H. Significant reduction of WT1 gene expression, possibly due to epigenetic alteration in Wilms' tumor. J Biochem 2003; 133: 303–8.
  • 33
    Matsunaga T,Sasaki F,Ohira M,Hashizume K,Hayashi A,Hayashi Y,Mugishima H,Ohnuma N. Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int 2003; 19: 142–6.
  • 34
    Harada K,Toyooka S,Maitra A,Maruyama R,Toyooka KO,Timmons CF,Tomlinson GE,Mastrangelo D,Hay RJ,Minna JD,Gazdar AF. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002; 21: 4345–9.
  • 35
    Nagai H,Naka T,Terada Y,Komazaki T,Yabe A,Jin E,Kawanami O,Kishimoto T,Konishi N,Nakamura M,Kobayashi Y,Emi M. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet 2003; 48: 65–9.
  • 36
    Agathanggelou A,Cooper WN,Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005; 65: 3497–508.
  • 37
    Dannenberg LO,Edenberg HJ. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 2006; 7: 181.
  • 38
    Esteller M,Corn PG,Baylin SB,Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225–9.
  • 39
    Abe M,Ohira M,Kaneda A,Yagi Y,Yamamoto S,Kitano Y,Takato T,Nakagawara A,Ushijima T. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005; 65: 828–34.
  • 40
    Koul S,McKiernan JM,Narayan G,Houldsworth J,Bacik J,Dobrzynski DL,Assaad AM,Mansukhani M,Reuter VE,Bosl GJ,Chaganti RS,Murty VV. Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer 2004; 3: 16.
  • 41
    Takayasu H,Horie H,Hiyama E,Matsunaga T,Hayashi Y,Watanabe Y,Suita S,Kaneko M,Sasaki F,Hashizume K,Ozaki T,Furuuchi K, et al. Frequent deletions and mutations of the β-catenin gene are associated with overexpression of Cyclin D1 and Fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res 2001; 7: 901–8.
  • 42
    von Schweinitz D,Kraus JA,Albrecht S,Koch A,Fuchs J,Pietsch T. Prognostic impact of molecular genetic alterations in hepatoblastoma. Med Pediatr Oncol 2002; 38: 104–8.
    Direct Link:
View Full Article with Supporting Information (HTML) Get PDF (288K)